



AMENDMENT UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE
GROUP 1614
PATENT APPLICATION

#16/B
(JLL)
JLL
3/11/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

MAR 10 2003

RECEIVED

In re application of

Docket No: Q58513

Ryuji UENO, et al.

Appln. No.: 09/816,655

Group Art Unit: 1614

Confirmation No.: 5746

Examiner: Zohreh A. FAY

Filed: March 26, 2001

For: APOPTOSIS INHIBITOR

AMENDMENT UNDER 37 C.F.R. § 1.116

ATTN: BOX AF
Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated November 5, 2002, which Applicants submit was prematurely indicated to be a final action, kindly amend the above-identified application as follows:

IN THE CLAIMS:

Please enter the following amended claims:

1. A method for treatment of a subject having an eye disorder associated with apoptosis, which comprises administering an effective amount of a 15-keto-prostaglandin compound represented by the following formula (I):

03/06/2003 SZEWDIE1 00000042 09816655

01 FC:1202

288.00 DP

03/11/2003 TSUGGS 00000003 DA# 194880 09816655

01 FC: 1202

54.00 CH